Similar companies
| Company | Business Outlook | |
|---|---|---|
 |
AmgenAMGN |
77 1.3% |
 |
Gilead SciencesGILD |
57 0% |
 |
Catalyst PharmaceuticalsCPRX |
100 0% |
 |
Inovio PharmaceuticalsINO |
23 0% |
 |
Anavex Life SciencesAVXL |
0 0% |
Month over Month
Employee view on business outlook (0 - 100)
| Oct 2024 | 35 | |
| Sep 2024 | 35 | |
| Aug 2024 | 38 | |
| Jul 2024 | 38 |
How do employees feel about the future at Immunitybio?
According to employees, the Business Outlook at Immunitybio is highly negative. This is reflected in the average rating of 36 out of 100, which is considered very low. But this rating (aggregated from the top review sites in the US) is up by 2.9% since the previous month.
Analyzing Business Outlook, how is Immunitybio performing compared to its industry peers?
Immunitybio underperforms its industry peers when it comes to Business Outlook, ranking in the 36th percentile.
How has the business outlook at Immunitybio changed over the last couple of months
In recent months, Immunitybio's employees have reported a shift towards a more negative business outlook, suggesting declining company morale and potentially leading to decreased market competitiveness and diminished company performance.
Why is it important to track the business outlook at Immunitybio?
Tracking a company's business outlook is important as a positive outlook can indicate future growth and profitability and attract new talent, while a negative outlook can discourage talent and imply demotivated employees. Additionally, data shows that companies with a high business outlook tend to perform better on the stock market compared to those with a lower business outlook.
Sign up and get more insights on the business outlook at Immunitybio.
